Over the weekend, Johnson & Johnson JNJ shared data from its TARIS platform assets (TAR-210 and TAR-200) in patients with different types of bladder cancer.
Goldman Sachs notes that the company has framed the platform as having a peak revenue potential of over $5 billion.
The analyst states that Johnson & Johnson emphasized the ease of administering their TARIS platform device-based therapy from a clinical management perspective.
The process resembles placing a catheter in the bladder or cystoscopy, requiring no general anesthesia and only minutes to perform, with no need for patient monitoring.
Johnson & Johnson anticipates reimbursement similar to catheter placement.
The company plans to submit data from their study in early 2025, targeting high-risk non–muscle-invasive bladder cancer (NMIBC) patients and those unresponsive to Bacillus Calmette-Guérin (BCG).
The broader market potential lies with BCG-naive patients, with ongoing Phase 3 studies expected to conclude in 2029.
The Goldman analyst writes that the program’s ongoing progress suggests it could effectively tackle unmet clinical needs in treating NMIBC, potentially replacing the longstanding BCG treatment.
The model estimates a peak sales potential of around $3 billion for TAR-200 alone, risk-adjusted at a 60% probability of success.
Price Action: JNJ shares are up 0.22% at $148.90 at last check Tuesday.
Photo via Shutterstock
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
